Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 324

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Plasma cell myeloma

Not recruiting

Study on Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone for Multiple Myeloma Patients Not Eligible for Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:University Of Cologne

Study on Atezolizumab, Carboplatin, and Etoposide for Adults with Advanced Large-Cell Neuroendocrine Lung Cancer

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Technische Universitat Dresden

Breast cancer+5

Not recruiting

Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluoroestradiol F-18
  • Sponsor:GE Healthcare Limited

Myelofibrosis+1

Not recruiting

Study of Fedratinib and Nivolumab for Patients with Myelofibrosis Resistant to JAK-inhibitor Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fedratinib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Acute myeloid leukaemia

Not recruiting

Study on Improving Survival in Acute Myeloid Leukemia for Adults Aged 18-60 Using Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cytarabine
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Cholangiocarcinoma

Not recruiting

Study on Preoperative Treatment with Gemcitabine, Cisplatin, Durvalumab, and Tremelimumab for Patients with Intrahepatic Cholangiocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Breast cancer metastatic+1

Not recruiting

Study of Alpelisib, Trastuzumab, and Fulvestrant for Patients with PIK3CA Mutated HER2+ Advanced Breast Cancer Previously Treated with Trastuzumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Volrustomig with a Drug Combination for Patients with Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Bladder transitional cell carcinoma

Not recruiting

Study comparing enfortumab vedotin versus chemotherapy combination (docetaxel, paclitaxel, vinflunine) in patients with previously treated advanced or metastatic bladder cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Astellas Pharma Global Development Inc.

Acute lymphocytic leukaemia

Not recruiting

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Hepatic cancer

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced Liver Cancer Resistant to Previous Immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Prostate cancer

Not recruiting

Study on the Effectiveness and Safety of Apalutamide and Stereotactic Radiotherapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Vychodoslovensky Onkologicky Ustav a.s.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.